OBJECTIVES: To assess cost-effectiveness of SAL/FP vs. mono-ICS in different Russian regions using OPTIMA pharmacoeconomic model. METHODS: Description and calculation steps of OPTIMA model were published in ISPOR Twelfth Annual European Congress Research Abstract #PRS8. Variable region-specific input data: drug prices and dosage proportion (from Farmexpert monitoring as of Q4 2009), medical tariffs (from regional government regulations), GDP per capita and average salary (from statistics service). Constant disease-specific data: frequency of controlled/uncontrolled asthma in arms (from clinical trial), number of unscheduled resources utilization and QoL in controlled and uncontrolled asthma (from prof. I.V.Demko’s observational study). Fixed combination SAL/FP (Seretide) was compared with mono-ICS (Beclomethasone, Fluticasone and Budesonide). ICERs (cost per QALY) were assessed for each 84 Russian regions. Regional WTP was assumed as three regional GDP per capita. 1 EUR = 38 RUB. RESULTS: Weighted average monthly pharmacotherapy cost varied from 1410RUB (in Kostroma) to 3376RUB (in Tula) for SAL/FP, and from 430RUB (in Kostroma) to 1524RUB (in Khanty-Mansi) for MonoICS. The differences were driven by proportion of low/medium/high doses. Medical tariffs varied dramatically as well: tariffs of outpatient visit varied from 107RUB (in Ivanovo and Dagestan) to 975RUB (in Yamal-Nenets), bed-day cost varies from 500RUB (in Kurgan) to 3123RUB (in Yamal-Nenets). GDP per capita were from 38110RUB (in Ingush) to 928374RUB (in Tyumen); average salary – from 9 125 RUB (in Dagestan) to 46480RUB (in Yamal-Nenets). SAL/FP was cost-saving (dominating) in 18 regions, cost-effective in 62 regions (ICER